LY-3076226

N/A

Report date: 2024/07/03 15:54:16

Base Information

Drug NameLY-3076226
Drug Alias NameLY-3076226anti-FGFR3 Ab IMC-D11
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPDB linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM4 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 3Tubulin
Therapy Area/IndicationsNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A